ID24228A - (+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4 - Google Patents

(+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4

Info

Publication number
ID24228A
ID24228A IDW20000033A ID20000033A ID24228A ID 24228 A ID24228 A ID 24228A ID W20000033 A IDW20000033 A ID W20000033A ID 20000033 A ID20000033 A ID 20000033A ID 24228 A ID24228 A ID 24228A
Authority
ID
Indonesia
Prior art keywords
disorders
norcisaprides
infected
intestinal disorders
treating gastro
Prior art date
Application number
IDW20000033A
Other languages
English (en)
Indonesian (id)
Inventor
Jozef Jan Pieter Heykants
Antonius Adrianus Hendr Megens
Willem Emiel Gusta Meuldermans
Joannes Adrianus Jac Schuurkes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ID24228A publication Critical patent/ID24228A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW20000033A 1997-07-11 1998-07-07 (+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4 ID24228A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202161 1997-07-11
EP98200661 1998-03-04

Publications (1)

Publication Number Publication Date
ID24228A true ID24228A (id) 2000-07-13

Family

ID=26146686

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000033A ID24228A (id) 1997-07-11 1998-07-07 (+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4

Country Status (31)

Country Link
US (2) US20030060485A1 (fr)
EP (1) EP1000029B1 (fr)
JP (1) JP3529102B2 (fr)
KR (1) KR100358374B1 (fr)
CN (1) CN1196681C (fr)
AT (1) ATE251139T1 (fr)
AU (1) AU757077B2 (fr)
BG (1) BG64824B1 (fr)
BR (1) BR9811676A (fr)
CA (1) CA2292480A1 (fr)
CO (1) CO4940432A1 (fr)
CZ (1) CZ296212B6 (fr)
DE (1) DE69818678T2 (fr)
DK (1) DK1000029T3 (fr)
EA (1) EA002362B1 (fr)
EE (1) EE04491B1 (fr)
ES (1) ES2209190T3 (fr)
HK (1) HK1025092A1 (fr)
HR (1) HRP20000004A2 (fr)
HU (1) HUP0003078A3 (fr)
ID (1) ID24228A (fr)
IL (1) IL133225A (fr)
MY (1) MY129130A (fr)
NO (1) NO315183B1 (fr)
NZ (1) NZ502207A (fr)
PL (1) PL190296B1 (fr)
PT (1) PT1000029E (fr)
SK (1) SK284941B6 (fr)
TR (1) TR200000020T2 (fr)
TW (1) TW553934B (fr)
WO (1) WO1999002496A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
EP1464333A3 (fr) * 1998-06-15 2004-12-15 Sepracor Inc. Procedes permettant de traiter l'apnee, la boulimie et d'autres troubles au moyen du norcisapride (-) optiquement pur
KR20060017570A (ko) * 1998-06-15 2006-02-23 세프라코 아이엔시. 무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도
EP1468685A3 (fr) * 1998-06-15 2004-12-15 Sepracor Inc. Procedes permettant de traiter l'apnee, la boulimie et d'autres troubles au moyen du norcisapride (+) optiquement pur
BR9911302A (pt) 1998-06-15 2001-03-13 Sepracor Inc Métodos para tratar bulimia, para tratar distúrbios mediados por atividade vagal, para tratar sìndrome de intestino irritável, para tratar apnéia ou distúrbios de apnéia, para prevenir ou controlar bulimia, distúrbios mediados por atividade vagal, sìndrome de intestino irritável, bradicardia ou bradiarritmia, asma, incontinência urinária, e, apnéia ou distúrbios da apnéia em um paciente
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2435816T3 (es) * 1999-08-03 2013-12-23 Icos Corporation Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
AU2001275326C1 (en) * 2000-06-07 2006-09-21 Aryx Therapeutics Treatment of gastroesophageal reflux disease using piperidine derivatives
JP2004513969A (ja) * 2000-11-24 2004-05-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 腸洗浄を促進するための5ht3アンタゴニスト、5ht4アゴニスト及び緩下薬を含んでなる三種類の組み合わせの使用
MXPA04003002A (es) * 2001-10-08 2004-07-15 Sun Pharmaceutical Ind Ltd Un sistema de administracion espacial de farmacos para agentes antiespasmodicos.
JP2003342186A (ja) * 2002-05-24 2003-12-03 Taisho Pharmaceut Co Ltd 鼻炎用内服液剤組成物
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2551686C (fr) 2004-01-07 2014-09-23 Ian Irwin Composes stereo-isomeres et methodes de traitement de troubles gastro-intestinaux et du systeme nerveux central
US20060247180A1 (en) * 2005-04-29 2006-11-02 Bergey James L Purgative composition and uses thereof
CA2620379C (fr) 2005-08-31 2015-02-24 Aryx Therapeutics, Inc. Methodes synthetiques et intermediaires de composes stereoisomeres utiles dans le traitement des troubles gastro-intestinaux et du systeme nerveux central
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
CA3069339A1 (fr) * 2017-07-19 2019-01-24 Ignyta, Inc. Compositions pharmaceutiques contenant de l'entrectinib
EP3820468A4 (fr) * 2018-07-11 2022-03-23 Duke University Utilisation de 5-hydroxytryptophane à libération prolongée dans le traitement de troubles gastro-intestinaux

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (fr) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide; derives
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
IL89848A (en) * 1988-04-07 1997-08-14 Sepracor Chiral ester derivatives
TW243449B (fr) * 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
TW294595B (fr) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
FR2717174B1 (fr) * 1994-03-14 1996-05-31 Sanofi Sa Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
PL337648A1 (en) 2000-08-28
NO20000093L (no) 2000-03-10
CZ461799A3 (cs) 2000-05-17
BG103934A (en) 2000-11-30
NO315183B1 (no) 2003-07-28
ES2209190T3 (es) 2004-06-16
EP1000029A1 (fr) 2000-05-17
EP1000029B1 (fr) 2003-10-01
CN1196681C (zh) 2005-04-13
EA002362B1 (ru) 2002-04-25
PT1000029E (pt) 2004-02-27
NO20000093D0 (no) 2000-01-07
DK1000029T3 (da) 2004-02-23
HK1025092A1 (en) 2000-11-03
HUP0003078A2 (hu) 2001-01-29
US20040176414A1 (en) 2004-09-09
DE69818678T2 (de) 2004-07-15
ATE251139T1 (de) 2003-10-15
BG64824B1 (bg) 2006-05-31
KR20010014027A (ko) 2001-02-26
SK284941B6 (sk) 2006-02-02
JP2000515560A (ja) 2000-11-21
HUP0003078A3 (en) 2002-02-28
CA2292480A1 (fr) 1999-01-21
TR200000020T2 (tr) 2000-09-21
EA200000057A1 (ru) 2000-08-28
SK182999A3 (en) 2000-08-14
EE200000014A (et) 2000-10-16
NZ502207A (en) 2001-08-31
BR9811676A (pt) 2000-09-19
KR100358374B1 (ko) 2002-10-25
IL133225A0 (en) 2001-03-19
EE04491B1 (et) 2005-06-15
HRP20000004A2 (en) 2000-12-31
PL190296B1 (pl) 2005-11-30
DE69818678D1 (de) 2003-11-06
MY129130A (en) 2007-03-30
CO4940432A1 (es) 2000-07-24
IL133225A (en) 2005-12-18
US20030060485A1 (en) 2003-03-27
JP3529102B2 (ja) 2004-05-24
AU757077B2 (en) 2003-01-30
CN1262675A (zh) 2000-08-09
TW553934B (en) 2003-09-21
AU8857598A (en) 1999-02-08
WO1999002496A1 (fr) 1999-01-21
CZ296212B6 (cs) 2006-02-15

Similar Documents

Publication Publication Date Title
ID24228A (id) (+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
RO116900B1 (ro) Derivaţi de dihidrobenzopiran, procedeu pentru prepararea acestora, intermediar pentru realizarea procedeului, compoziţie farmaceutică şi metodă de tratament
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
SI1274685T1 (sl) Derivat piridin-1-oksida in postopek njegove transformacije v farmacevtsko ucinkovite sestavine
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
UA41353C2 (uk) Похідні алкілбензоїлгуанідинів, спосіб їх одержання, фармацевтична композиція, що має аритмічну активність
NO308658B1 (no) Sammenføyde isoquinoliner som dopamin-reseptor-ligander
MY133438A (en) Morpholinobenzamide salts
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
IL146962A0 (en) Aminotetralin derivatives for the therapy of cardiovascular diseases
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
DK0796256T3 (da) Fremgangsmåde til fremstilling af ranitidin
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler
HUP0103992A2 (hu) Pregnán-glükuronidok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.